Article
EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features.
Diagnostic pathology - 26 Apr 2016
Guo Shuangping, Li Xia, Rohr Joseph, Wang Yingmei, Ma Shirong, Chen Peng, Wang Zhe
Abstract excerpt
BACKGROUND: Enhancer of zest homolog 2 (EZH2), a histone 3 methyltransferase, is associated with aggressive behavior of many tumors and is a promising target of molecular therapy. METHODS: To better elucidate the relevance of EZH2 in breast cancer subtypes, we evaluated EZH2 expression in 226 invasive breast carcinomas with four distinct immunophenotypes and in association with clinicopathological features....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.